Literature DB >> 23700716

Chromophobe renal cell carcinoma with sarcomatoid differentiation: a clinicopathologic study of 14 cases.

Scott R Lauer1, Ming Zhou, Viraj A Master, Adeboye O Osunkoya.   

Abstract

OBJECTIVE: To investigate the clinicopathologic features of chromophobe renal cell carcinoma with sarcomatoid differentiation. STUDY
DESIGN: A search was made through the surgical pathology and expert consult files of two major academic institutions from 2003 to 2011 for cases of chromophobe renal cell carcinoma with sarcomatoid differentiation.
RESULTS: Fourteen patients were identified. The patients included 9 males (64%) and 5 females (36%). The mean patient age was 60.4 years (range, 40-82 years). There was a left-sided predominance: left (9 patients) and right (5 patients). The mean tumor size was 14.6 cm (range, 9.5-28.0 cm), and the mean percentage sarcomatoid differentiation was 67% (range, 30-99%). All tumors exhibited moderate to extensive areas of necrosis. The nonsarcomatoid component in all cases demonstrated classic features of chromophobe renal cell carcinoma. Nine patients (64%) had pT3 disease and 5 patients (36%) had pT4 disease. Five patients (36%) had positive surgical margins. Three patients (21%) had tissue diagnosis of metastatic disease at the time of initial surgery. Six patients (43%) had subsequent pathologic and/or radiologic evidence of multiple or isolated metastatic disease. Follow-up information was available in all 14 patients. Mean follow-up time was 16 weeks (range, 2-84 weeks). Ten of 14 patients (71%) died of disease, 9 of those within 6 months (mean survival time of 10 weeks), 3 patients (21%) were alive with disease, and only 1 patient (7%) was alive with no evidence of disease.
CONCLUSION: This study is one of the largest series to date specifically examining the clinicopathologic features of sarcomatoid chromophobe renal cell carcinoma in radical nephrectomy specimens and confirms the observation that these tumors behave more aggressively than conventional clear cell renal cell carcinoma or papillary renal cell carcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 23700716

Source DB:  PubMed          Journal:  Anal Quant Cytopathol Histpathol        ISSN: 2578-742X


  5 in total

1.  Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes.

Authors:  Yasser Ged; Ying-Bei Chen; Andrea Knezevic; Jozefina Casuscelli; Almedina Redzematovic; Renzo G DiNatale; Maria I Carlo; Chung-Han Lee; Darren R Feldman; Sujata Patil; A Ari Hakimi; Paul Russo; Robert J Motzer; Martin H Voss
Journal:  Clin Genitourin Cancer       Date:  2019-04-01       Impact factor: 2.872

2.  Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.

Authors:  Jozefina Casuscelli; Maria F Becerra; Kenneth Seier; Brandon J Manley; Nicole Benfante; Almedina Redzematovic; Christian G Stief; James J Hsieh; Satish K Tickoo; Victor E Reuter; Jonathan A Coleman; Paul Russo; Irina Ostrovnaya; A Ari Hakimi
Journal:  Clin Genitourin Cancer       Date:  2019-06-26       Impact factor: 2.872

3.  BSND and ATP6V1G3: Novel Immunohistochemical Markers for Chromophobe Renal Cell Carcinoma.

Authors:  Kazuya Shinmura; Hisaki Igarashi; Hisami Kato; Kenji Koda; Hiroshi Ogawa; Seishiro Takahashi; Yoshiro Otsuki; Tatsuaki Yoneda; Yuichi Kawanishi; Kazuhito Funai; Tatsuya Takayama; Seiichiro Ozono; Haruhiko Sugimura
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

4.  Chromophobe renal cell carcinoma with sarcomatoid changes: case report and review of literature.

Authors:  Dhiraj Daga; Rohitashwa Dana; Nirupama Kothari
Journal:  Cent European J Urol       Date:  2014-04-17

5.  Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.

Authors:  Stephanie L Skala; Xiaoming Wang; Yuping Zhang; Rahul Mannan; Lisha Wang; Sathiya P Narayanan; Pankaj Vats; Fengyun Su; Jin Chen; Xuhong Cao; Javed Siddiqui; Pedram Argani; Marcin P Cieślik; Thomas J Giordano; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Eur Urol       Date:  2020-04-13       Impact factor: 20.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.